Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Proposed T2T NEDA Trial


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Proposed T2T NEDA Trial

  1. 1. PROPOSED NEDA Rx Trial Relapsing-remitting MS (RRMS) NEDA = No Evident of Disease Activity T2T = treat-2-target RES = rapidly evolving severe MS HAD = highly-active disease activity Active disease? N Observation Y RES disease? Y Rx with Nz N Randomise Current practice Current 1st-line treatments IFNb, GA (Teri, BG12) Current 1st-line treatments IFNb, GA (Teri, BG12) 6-monthly* clinical F-UP Switch in lower tier IFNb, GA (Teri, BG12) T2T-NEDA 6-monthly* clinical/MRI F-UP Y Clinical responder? Y Clinical/MRI responder? N N HAD or RES? N Escalation/switch in upper tier natalizumab, fingolimod (Alemz) Y Escalation/switch to upper tier natalizumab, fingolimod (Alemz) 3-yr 1° outcome: confirmed disability progression 5-yr 1° outcome: time to confirmed EDSS 4.0 2° outcomes: MRI etc. * A clinical relapse between 6-monthly visits will trigger an unscheduled assessment for switching/escalation GG, version 1.0 3rd Jan 2014